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ORGAN FUNCTION AND QUALITY OF LIFE CORRELATES AT RANDOMIZA-
TION ON THE SCOT (SCLERODERMA: CYCLOPHOSPHAMIDE OR
TRANSPLANTATION) TRIAL
Sullivan, K.M.1, Froshaug, D.B.2, Furst, D.E.3, Nash, R.A.4,
Mayes, M.D.5, Crofford, L.J.6, McSweeney, P.A.7, Goldmuntz, E.A.8,
Keyes-Elstein, L.2, Khanna, D.3 1Duke University Medical Center,
Durham, NC; 2Rho Federal System, Chapel Hill, NC; 3University of
California-Los Angeles, Los Angeles, CA; 4Fred Hutchinson Cancer
Research Center, Seattle, WA; 5University of Texas-Houston, Houston,
TX; 6University of Kentucky, Lexington, KY; 7Rocky Mountain Cancer
Centers, Denver, CO; 8National Institutes of Health, Bethesda, MD
Objective:Autoimmune diseases offer unique opportunities to mea-
sure disease burden and response to immunomodulation with hema-
topoietic cell transplantation (HCT). To study baseline impairments
in health-related quality of life (HR-QOL), we analyzed correlates of
HR-QOL indices among patients with diffuse systemic sclerosis
(SSc) participating in the SCOT trial.
Methods: Subjects with poor prognosis SSc were enrolled in the on-
going multicenter trial comparing immunosuppression with 12
monthly infusions of CY (750mg/m2) vs. immunoablation followed
by CD34-selected autologous HCT. Entry criteria are detailed at
the study website (www.sclerodermatrial.org). Validated HR-QOL
indices included the short form 36 (SF-36) physical component sum-
mary (PCS) and mental component summary (MCS), health assess-
ment questionnaire-disability index (HAQ-DI), and the UCLA
gastrointestinal instrument (GIT 2.0). We assessed Pearson correla-
tions between HR-QOL indices and objective disease measures:
coefficients. /5 0.32 (representing R2. /5 10%) were considered
meaningful associations.
Results: 61 subjects were evaluated before treatment: 40 were fe-
male; mean age was 46 and disease duration was 3.8 yr; mean
(SD) % predicted FVC was 74.6 (16.2) and DLCO was 50.5
(8.2). Mean modified Rodnan Skin Score (mRSS) was 30.9 (9.5).
mRSS measures dermal thickening ranging from 0 (none) to 51
(total body sclerosis). Baseline mean PCS was 27.4 which is 2.3
SD below the US general population. The 61 patients had moder-
ate functional disability (mean HAQ-DI 1.4) while the mean total
GIT (measured in 21 pts) was 0.76, where 0.4 signifies moderate se-
verity. For comparison, subjects with diffuse SSc enrolled in the
Scleroderma Lung Study (comparing CY with placebo, Tashkin
NEJM 2006) had a higher (better) baseline PCS (32.1) and
lower (better) HAQ-DI (1.02) (Khanna Arthritis Rheum 2005).
The table presents Pearson’s correlations between HR-QOL indi-
ces and mRSS, FVC and DLCO. Correlations (r) with magnitudes
of . / 5 0.32 are bolded.
Table 1. Baseline Pearson’s Correlation Coefficients (r) for
HR-QOL Measures versus Dermal and Pulmonary Measures
Variables mRSS1 FVC2 DLCO2SHAQ
HAQ-DI1 0.58* 0.02 -0.41*
Pain VAS1 0.05 0.05 0.00
SF-36
SF-36 PCS 2 -0.47* 0.02 0.25
SF-36 MCS2 -0.03 0.08 0.13
SF-36 Physical functioning2 -0.47* 0.10 0.45*
SF-36 Role limitations2 -0.40* -0.01 0.31*
SF-36 Pain 2 -0.20 0.10 0.08
SF-36 General health 2 -0.15 -0.07 0.07
SF-36 Vitality2 -0.12 0.11 0.06
SF-36 Social functioning 2 -0.17 0.00 0.07
SF-36 Role emotional 2 -0.15 0.10 0.25
SF-36 Mental health2 -0.04 0.01 0.17(Continued )Table 1. (Continued )Variables mRSS1 FVC2 DLCO2UCLA GIT 2.0
Reflux scale1 -0.34* 0.32 0.24
Distention scale1 -0.47* 0.27 0.41
Diarrhea1 0.09 -0.13 -0.23
Constipation1 0.08 -0.11 -0.30
Emotional well-being1 -0.13 -0.05 0.07
Social functioning1 0.07 0.33 -0.23
GIT Total Score -0.29 0.24 0.171Lower scores denote better HR-QOL or lower intensity of symptoms.
2Higher scores denote better HR-QOL or lower intensity.
*Correlations significant at p<0.05. %R 2 >10% (r>0.32) are bolded.
Conclusions:Patients in the SCOT study had marked baseline im-
pairments in physical health. Objective disease measures of dermal
and pulmonary involvement correlated with symptom burden.
Longitudinal analysis (12 test repetitions over 72 mo) at study
completion will offer unique rigor in HCT trials, provide a rich
basis for comparisons with immune and mechanistic studies, and
characterize alterations in HR-QOL indices across the two treat-
ments of SSc.AUTOLOGOUS TRANSPLANTS114
DOUBLE HIGH DOSE SALVAGE THERAPY WITH DOSE-INTENSIFIED
CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN (DICEP) RE-INDUC-
TION FOLLOWED BY HIGH-DOSE MELPHALAN (HDM) AND AUTOLO-
GOUS STEM CELL TRANSPLANTATION (ASCT) CONSOLIDATION FOR
RELAPSED/REFRACTORY HODGKIN LYMPHOMA
Shafey, M., Duan, Q., Russell, J.A., Duggan, P., Balogh, A.,
Stewart, D.A. University of Calgary, Tom Baker Cancer Centre, Calgary,
AB, Canada
The purpose of this study was to retrospectively review our results
of double high-dose therapy with DICEP re-induction followed by
HDM and ASCT for this patient population.
Between June 1995 andNovember 2009, 73 patients with relapsed
(43) or refractory (30) classical HL were treated with DICEP (dose-
intensified cyclophosphamide 5.25 g/m2, etoposide 1050 mg/m2,
and cisplatin 105 mg/m2) with autologous blood stem cell apheresis
performed upon hematopoietic recovery, followed 2-3 weeks later by
HDM (melphalan 200 mg/m2) and ASCT.
Patient characteristics included: age 20-63 years (median 37);
bulk. 5 cm5 39, bulk. 10 cm5 12; number of prior chemother-
apy regimen(s) failed 15 63, 2-45 10; prior radiotherapy5 30; ini-
tial time to progression\3months5 30, 3-12 months5 21, and.
12 months 5 22; median time from diagnosis to ASCT 15 months
(range 4-324); B symptoms 5 18; and International Prognostic
Score (IPS) 0-15 19, 25 26, 35 17, 4-75 11. DICEP chemother-
apy resulted in successful stem cell mobilization in 71 patients
(97%), with a median CD341 cell count of 15.6 x106/kg (range
4.7-70.9 x106/kg). 63 patients (86%) responded to DICEP, includ-
ing 13 complete responses (18%). 4 patients did not proceed to
HDM-ASCT; two failed to mobilize stem cells, one experienced
grade IV infection, and one experienced bleeding and respiratory
arrest with anoxic brain injury following removal of an internal
jugular apheresis catheter following stem cell collection. The latter
patient was the only treatment-related death following DICEP.
With a median follow-up of 56 months post-DICEP (range 3-
170 months), the 5-year PFS and OS rates were 61% [95%CI 5
49-72%] and 80% [95%CI 5 69-89%], respectively. The 5 year
PFS was 65% vs. 30% for DICEP responders vs. non-respondersS195
